E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33%
Market Cap: 92.2B EUR

EV/EBITDA
Enterprise Value to EBITDA

-560.9
Current
-532.5
Median
4.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-560.9
=
Enterprise Value
94.2B EUR
/
EBITDA
-190.9m USD
EBITDA Growth EV/EBITDA to Growth
US
E
Epizyme Inc
F:EPE
Average EV/EBITDA: 32.2
Negative Multiple: -560.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 430.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
17%
1.4
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.4
11%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -658.7 N/A N/A
NL
argenx SE
XBRU:ARGX
133.9
727%
0.2

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A